Understanding Ocular Graft-Versus-Host Disease After Bone Marrow Transplant
Ocular Graft-Versus-Host-Disease After Allogeneic Haematopoietic Stem Cell Transplantation: A Territory-Wide Prospective Cohort
This study is trying to understand how common eye problems are in people who have had a bone marrow transplant and see if certain factors can help improve their care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT05170347 on ClinicalTrials.gov |
What this trial studies
This observational study aims to establish a territory-wide cohort of patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT) to investigate ocular graft-versus-host disease (oGVHD). The study will focus on the prevalence and impact of oGVHD, which affects a significant percentage of HSCT patients and can lead to severe complications such as visual loss. By collecting microbiome and tear samples from patients and their family members, the researchers hope to identify risk factors and improve management strategies for oGVHD. The study is conducted in collaboration with the Department of Haematology at Queen Mary Hospital.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and above who have undergone allogeneic HSCT at Queen Mary Hospital within the last two years.
Not a fit: Patients who have undergone autologous HSCT or are unable to attend follow-up visits may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better understanding and management of ocular graft-versus-host disease, improving the quality of life for affected patients.
How similar studies have performed: While there is limited research specifically on oGVHD, studies on GVHD management have shown varying degrees of success, indicating that this area is still evolving.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged 18 or above * Underwent allogeneic HSCT in QMH in the two-year recruitment period Exclusion Criteria: * Underwent autologous HSCT * Patient unable to attend follow-up visits Family Control Subjects The research team will invite an accompanying family member to be the family control. Microbiome and tear samples will be collected for comparison. The sample collection schedule is the same as the corresponding post-HSCT case.
Where this trial is running
Hong Kong
- Department of Ophthalmology, LKS Faculty of Medicine, The University of Hong Kong — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Principal investigator: Allie Lee — The University of Hong Kong
- Study coordinator: Allie Lee
- Email: aleeni@hku.hk
- Phone: +852 39621405
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.